Close

Biophytis (BPTS) Announces Proposed Common Offering and Nasdaq Listing

Go back to Biophytis (BPTS) Announces Proposed Common Offering and Nasdaq Listing

Biophytis SA (BPTS) Begins Patient Recruitment in Brazil and U.S. for Part 2 of Phase 2-3 COVA Trial

February 3, 2021 5:52 AM EST

Biophytis SA (NASDAQ: BPTS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces that patient recruitment at most clinical centers in Brazil and the United States will begin for Part 2 of its COVA Study assessing Sarconeos (BIO101) as a potential treatment for acute respiratory failure associated with COVID-19.

Enrollment for Part 1 of the COVA Study has been completed with... More